These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11423459)

  • 1. CMVR diagnoses and progression of CD4 cell counts and HIV viral load measurements in HIV patients on HAART.
    Zambarakji HJ; Newson RB; Mitchell SM
    Br J Ophthalmol; 2001 Jul; 85(7):837-41. PubMed ID: 11423459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study.
    Mitchell SM; Membrey WL; Youle MS; Obi A; Worrell S; Gazzard BG
    Br J Ophthalmol; 1999 Jun; 83(6):652-5. PubMed ID: 10340970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis.
    Walmsley SL; Raboud J; Angel JB; Mazzulli T; Shen S; Casciaro L; Young CD; Moussa G; Gough K; Rachlis A; Hopkins J
    HIV Clin Trials; 2006; 7(1):1-9. PubMed ID: 16632459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus retinitis in advanced HIV-infected patients treated with protease inhibitors: incidence and outcome over 2 years.
    Labetoulle M; Goujard C; Frau E; Rogier H; Niessen F; Furlan V; Lantz O; Lecointe D; Delfraissy JF; Offret H
    J Acquir Immune Defic Syndr; 1999 Nov; 22(3):228-34. PubMed ID: 10770342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of protease inhibitors on the course of CMV retinitis in relation to CD4+ lymphocyte responses in HIV+ patients.
    van den Horn GJ; Meenken C; Danner SA; Reiss P; de Smet MD
    Br J Ophthalmol; 1998 Sep; 82(9):988-90. PubMed ID: 9893585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
    Mocroft A; Phillips AN; Miller V; Gatell J; van Lunzen J; Parkin JM; Weber R; Roge B; Lazzarin A; Lundgren JD;
    AIDS; 2001 Jan; 15(2):201-9. PubMed ID: 11216928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different kinetics of immunologic recovery using nelfinavir or lopinavir/ritonavir-based regimens in children with perinatal HIV-1 infection.
    De Luca M; Miccinesi G; Chiappini E; Zappa M; Galli L; De Martino M
    Int J Immunopathol Pharmacol; 2005; 18(4):729-35. PubMed ID: 16388722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
    Kirk O; Mocroft A; Pradier C; Bruun JN; Hemmer R; Clotet B; Miller V; Viard JP; Phillips AN; Lundgren JD;
    AIDS; 2001 May; 15(8):999-1008. PubMed ID: 11399982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of highly active antiretroviral therapy on the development of CMV disease in HIV positive patients at high risk for CMV disease.
    Verbraak FD; Boom R; Wertheim-van Dillen PM; van den Horn GJ; Kijlstra A; de Smet MD
    Br J Ophthalmol; 1999 Oct; 83(10):1186-9. PubMed ID: 10502584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of maintenance therapy in patients with quiescent cytomegalovirus retinitis and elevated CD4+ counts.
    Vrabec TR; Baldassano VF; Whitcup SM
    Ophthalmology; 1998 Jul; 105(7):1259-64. PubMed ID: 9663231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy.
    Jouan M; Savès M; Tubiana R; Carcelain G; Cassoux N; Aubron-Olivier C; Fillet AM; Nciri M; Sénéchal B; Chêne G; Tural C; Lasry S; Autran B; Katlama C;
    AIDS; 2001 Jan; 15(1):23-31. PubMed ID: 11192865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire.
    Adjé-Touré CA; Cheingsong R; Garcìa-Lerma JG; Eholié S; Borget MY; Bouchez JM; Otten RA; Maurice C; Sassan-Morokro M; Ekpini RE; Nolan M; Chorba T; Heneine W; Nkengasong JN
    AIDS; 2003 Jul; 17 Suppl 3():S49-54. PubMed ID: 14565609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
    HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMV retinitis recurs after stopping treatment in virological and immunological failures of potent antiretroviral therapy.
    Torriani FJ; Freeman WR; Macdonald JC; Karavellas MP; Durand DM; Jeffrey DD; Meylan PR; Schrier RD
    AIDS; 2000 Jan; 14(2):173-80. PubMed ID: 10708288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis.
    Rolla VC; da Silva Vieira MA; Pereira Pinto D; Lourenço MC; de Jesus Cda S; Gonçalves Morgado M; Ferreira Filho M; Werneck-Barroso E
    Clin Drug Investig; 2006; 26(8):469-79. PubMed ID: 17163279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy.
    Song MK; Karavellas MP; MacDonald JC; Plummer DJ; Freeman WR
    Retina; 2000; 20(2):151-5. PubMed ID: 10783947
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.
    Miller V; Sabin CA; Phillips AN; Rottmann C; Rabenau H; Weidmann E; Rickerts V; Findhammer S; Helm EB; Staszewski S
    AIDS; 2000 Sep; 14(14):2129-36. PubMed ID: 11061654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of nelfinavir, ritonavir, or delavirdine in combination with saquinavir-SGC and stavudine in treatment-experienced HIV-1-infected patients.
    Smith D; Hales G; Roth N; Law M; Ray J; Druett J; Mitchell J; Mills G; Doong N; Franklin R;
    HIV Clin Trials; 2001; 2(2):97-107. PubMed ID: 11590517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly active antiretroviral therapy-associated regression of cytomegalovirus retinitis: long-Term results in a small case series.
    Reed JB; Briggs JW; McDonald JC; Freeman WR; Morse LS
    Retina; 2001; 21(4):339-43. PubMed ID: 11508879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.